EPEMED, the European PErsonalised MEdicine Diagnostics association announces the appointment of its founding board of directors

29-Oct-2009 - France

Newly created European PErsonalised medicine diagnostics association EPEMED, announced the appointment of its founding board of directors.

EPEMED, a membership association formed in August 2009 as a not-for- profit organisation, will provide a platform for harmonisation in the development and implementation of value-based diagnostics across Europe, to make personalised medicine a reality. Personalised Medicine, the use of a person’s clinical, genetic, genomic and environmental information to more precisely and accurately select a medication and its dose for each individual patient, will both improve care and lower costs.

EPEMED has appointed experts in the field of personalised medicine and molecular diagnostics as its founding board of directors:

- Alain Huriez, M.D., Chairman, CEO TcLand Expression

- Mara Aspinall, President & CEO, On-Q-ity, ex. president, Genzyme Genetics

- Vincent Fert, President & CEO Ipsogen

- Werner Kroll, Ph.D., Head Diagnostics Research and Innovation Novartis Molecular Diagnostics

- Iain D. Miller, Ph.D., Senior Director, Oncology Strategy and Theranostics, bioMerieux

- Herman Spolders, BVBA, CEO Oncomethylome Sciences

- Patrick F. Terry, founder Genomic Health & PMC, CEO Technic Solutions

Other news from the department people

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.